Extract from the Register of European Patents

EP Citations: EP2265251

Cited inInternational search
Type:Patent literature
Publication No.:US6743439  [X]
 (CASTILLO ERNESTO J et al.) [X] 1-10,13-20 * example 5 *
Type:Patent literature
Publication No.:WO0003736  [X]
 (ALCON LAB INC et al.) [X] 1-4,6-10,13-20 * page 7, line 11 - line 30 * * examples 1-7 * * claims 1-9 *
Type:Patent literature
Publication No.:EP1547599  [X]
 (SANTEN PHARMACEUTICAL CO LTD et al.) [X] 1-4,6,7,9,10,13-20 * page 3, paragraph 22 * * table 2 * * table 3 * * examples *
Type:Patent literature
Publication No.:US2004082660  [XI]
 (UENO RYUJI et al.) [X] 1-4,9,10,12-20 * page 1, paragraph 14 * * table 1 * * claims 1-16 *[I] 11
Type:Patent literature
Publication No.:WO9841208  [X]
 (CIBA GEIGY AG et al.) [X] 1,3,4,10,15-17,19,20 * examples 1-14 *
Type:Patent literature
Publication No.:WO9825620  [XY]
 (ALCON LAB INC et al.) [X] 21-25,27,30,31,37,38,40,41 * example 4 * * claims 1-18 *[Y] 1-41
Type:Patent literature
Publication No.:US5932572  [XY]
 (DEAN THOMAS R et al.) [X] 21-25,27,30-32,37,40,41 * table 1 * * examples 1,2 *[Y] 1-41
Type:Patent literature
Publication No.:WO9819680  [XY]
 (ALCON LAB INC et al.) [X] 21-25,27-31,34-38,40,41 * examples 1-8 * * claims 1-6 *[Y] 1-41
Type:Patent literature
Publication No.:WO9853809  [XY]
 (MERCK & CO INC et al.) [X] 21-25,27,30-32,37,40,41 * Examples *[Y] 1-41
Type:Non-patent literature
Publication information:[Y]   FELDMAN ET AL: "Comparison of the Ocular Hypotensive Efficacy of Adjunctive Brimonidine 0.15% or Brinzolamide 1% in Combination with Travoprost 0.004%", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 114, no. 7, 1 July 2007 (2007-07-01), pages 1248 - 1254.E2, XP022137571, ISSN: 0161-6420 [Y] 1-41 * the whole document *
Cited inExamination
Type:Patent literature
Publication No.:WO9729752  
Cited inOpposition
Type:Patent literature
Publication No.:US6743439  
Type:Patent literature
Publication No.:WO0003736  
Type:Patent literature
Publication No.:EP1547599  
Type:Patent literature
Publication No.:US2004082660  
Type:Patent literature
Publication No.:WO9841208  
Type:Patent literature
Publication No.:WO9729752  
Type:Patent literature
Publication No.:US2009149546  
Type:Patent literature
Publication No.:US3711708  
Type:Patent literature
Publication No.:US11192008  
Type:Patent literature
Publication No.:EP2599475  
Type:Patent literature
Publication No.:WO0003736  
Type:Patent literature
Publication No.:WO9729752  
Type:Patent literature
Publication No.:EP1321144  
Type:Non-patent literature
Publication information:  LABBE ET AL.: "comparison of toxicological profiles of benzalkonium chloride and polyquaternium 1 an experimental study", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 22, no. 4, 2006, pages 267 - 278, XP055264197
DOI: http://dx.doi.org/10.1089/jop.2006.22.267
Type:Non-patent literature
Publication information:  BAUDOUIN ET AL.: "in vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 48, no. 9, September 2007 (2007-09-01), pages 4123 - 4128, XP002607568
DOI: http://dx.doi.org/10.1167/IOVS.07-0266
Type:Non-patent literature
Publication information:  BERNAL ET AL: "Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives", CURRENT EYE RESEARCH, vol. 10, no. 7, 1991, pages 645 - 656, XP055265030
DOI: http://dx.doi.org/10.3109/02713689109013856
Type:Non-patent literature
Publication information:  AMMAR ET AL: "Effects of Benzalkonium Chloride- Preserved, Polyquad-Preserved, and sofZia-Preserved Topical Glaucoma Medications on Human Ocular Epithelial Cells", ADV THER, vol. 27, no. 11, 2010, pages 1 - 9, XP055097387
DOI: http://dx.doi.org/10.1007/s12325-010-0070-1
Type:Non-patent literature
Publication information:  LABB ET AL.: "Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study.", J OCUL PHARMACOL THER., vol. 22, no. 4, August 2006 (2006-08-01), pages 267 - 78, XP055264197
DOI: http://dx.doi.org/10.1089/jop.2006.22.267
Cited inby applicant
Type:Patent literature
Publication No.:US6743439  
Type:Patent literature
Publication No.:WO0003736  
Type:Patent literature
Publication No.:EP1547599  
Type:Patent literature
Publication No.:US2004082660  
Type:Patent literature
Publication No.:WO9841208  
Type:Patent literature
Publication No.:WO9825620  
Type:Patent literature
Publication No.:US5932572  
Type:Patent literature
Publication No.:WO9819680  
Type:Patent literature
Publication No.:WO9823809  
Type:Patent literature
Publication No.:US3931319  
Type:Patent literature
Publication No.:US4027020  
Type:Patent literature
Publication No.:US4407791  
Type:Patent literature
Publication No.:US4525346  
Type:Patent literature
Publication No.:US4836986  
Type:Patent literature
Publication No.:US5037647  
Type:Patent literature
Publication No.:US5300287  
Type:Patent literature
Publication No.:US5817277  
Type:Patent literature
Publication No.:US6503497  
Type:Patent literature
Publication No.:US5741817  
Type:Patent literature
Publication No.:US6319464  
Type:Patent literature
Publication No.:US6348190  
Type:Patent literature
Publication No.:US6482799  
Type:Patent literature
Publication No.:US5320843  
Type:Patent literature
Publication No.:US5221664  
Type:Patent literature
Publication No.:US6034043  
Type:Patent literature
Publication No.:US4522806  
Type:Patent literature
Publication No.:US6017861  
Type:Patent literature
Publication No.:US2002122831  
Type:Patent literature
Publication No.:WO9109523  
Type:Patent literature
Publication No.:JP2003104870  
Cited inother
Type:Patent literature
Publication No.:WO9729752  
Type:Non-patent literature
Publication information:  "ICH TOPIC Q 3 B (R2) IMPURITIES IN NEW DRUG PRODUCTS", EUROPEAN MEDICINES AGENCY, June 2006 (2006-06-01), pages 1 - 14, XP003033468